Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Clinical trial NCT04924101 · COMPLETED
Trial details
- NCT number
- NCT04924101
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-15
- Primary completion
- 2025-06-23
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.